Cancer 2015: a longitudinal, whole of system study of genomic cancer medicine
Genomic cancer medicine promises revolutionary change in oncology. The impacts of 'personalized medicine', based upon a molecular classification of cancer and linked to targeted therapies, will extend from individual patient outcomes to the health economy at large. To address the 'whole-of-system' impact of genomic cancer medicine, we have established a prospective cohort of patients with newly diagnosed cancer in the state of Victoria, Australia, about whom we have collected a broad range of clinical, demographic, molecular, and patient-reported data, as well as data on health resource utilization. Our goal is to create a model for investigating public investment in genomic medicine that maximizes the cost:benefit ratio for the Australian community at large.
|Authors||Thomas, D.M.; Fox, S.; Lorgelly, P.K.; Ashley, D.; Richardson, G.; Lipton, L.; Parisot, J. P.; Lucas, M.; McNeil, J.; Wright M for the Cancer 2015 Investigators, .;|
|Responsible Garvan Author|
|Publisher Name||DRUG DISCOVERY TODAY|
|URL link to publisher's version||http://www.ncbi.nlm.nih.gov/pubmed/26494144|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/13076|